Have a feature idea you'd love to see implemented?
Let us know!
MYGN Myriad Genetics Inc
Price (delayed)
$13.5
Market cap
$1.23B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.28
Enterprise value
$1.27B
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing
Highlights
The EPS has soared by 62% YoY and by 28% from the previous quarter
The company's net income has surged by 58% YoY and by 25% QoQ
Key stats
What are the main financial stats of MYGN
Market
Valuations
Earnings
Shares outstanding
91.04M
Market cap
$1.23B
Enterprise value
$1.27B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.68
Price to sales (P/S)
1.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.54
Revenue
$823.6M
Gross profit
$569.5M
Net income
-$116M
EBIT
-$113.6M
EBITDA
-$42.7M
Free cash flow
-$107.3M
Per share
Balance sheet
Liquidity
EPS
-$1.28
EPS diluted
-$1.28
Free cash flow per share
-$1.18
Book value per share
$8.06
Revenue per share
$9.06
TBVPS
$5.31
Total assets
$1.08B
Total liabilities
$349.6M
Debt
$143.1M
Equity
$731.7M
Working capital
$138.9M
Debt to equity
0.2
Current ratio
1.9
Quick ratio
1.46
Net debt/EBITDA
-1.01
Margins
Efficiency
Dividend
EBITDA margin
-5.2%
Gross margin
69.1%
Net margin
-14.1%
Operating margin
-14.1%
Return on assets
-10.5%
Return on equity
-15.4%
Return on invested capital
-30%
Return on capital employed
-12.3%
Return on sales
-13.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MYGN stock price
How has the Myriad Genetics stock price performed over time
Intraday
-1.75%
1 week
2.51%
1 month
-16.51%
1 year
-33.73%
YTD
-29.47%
QTD
-50.71%
Financial performance
How have Myriad Genetics's revenue and profit performed over time
Revenue
$823.6M
Gross profit
$569.5M
Operating income
-$115.8M
Net income
-$116M
Gross margin
69.1%
Net margin
-14.1%
The company's operating margin has surged by 63% YoY and by 27% QoQ
The net margin has soared by 62% YoY and by 27% from the previous quarter
The company's net income has surged by 58% YoY and by 25% QoQ
The operating income has soared by 58% YoY and by 26% QoQ
Growth
What is Myriad Genetics's growth rate over time
Valuation
What is Myriad Genetics stock price valuation
P/E
N/A
P/B
1.68
P/S
1.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.54
The EPS has soared by 62% YoY and by 28% from the previous quarter
MYGN's price to book (P/B) is 38% lower than its last 4 quarters average of 2.7 and 20% lower than its 5-year quarterly average of 2.1
The company's equity rose by 7% YoY
The P/S is 43% lower than the last 4 quarters average of 2.6 and 40% lower than the 5-year quarterly average of 2.5
Myriad Genetics's revenue has increased by 12% YoY and by 2.7% QoQ
Efficiency
How efficient is Myriad Genetics business performance
The ROS has soared by 64% YoY and by 28% from the previous quarter
MYGN's return on equity has surged by 56% year-on-year and by 26% since the previous quarter
Myriad Genetics's return on assets has surged by 55% YoY and by 24% QoQ
The return on invested capital has surged by 52% year-on-year and by 23% since the previous quarter
Dividends
What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MYGN.
Financial health
How did Myriad Genetics financials performed over time
The quick ratio has soared by 52% year-on-year
Myriad Genetics's current ratio has increased by 50% YoY but it has decreased by 3.1% from the previous quarter
The debt is 80% less than the equity
The debt to equity is down by 31% year-on-year but it is up by 5% since the previous quarter
The debt has contracted by 29% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.